RAUORA: Cytisine Versus Varenicline for Smoking Cessation

Trial Profile

RAUORA: Cytisine Versus Varenicline for Smoking Cessation

Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Cytisine (Primary) ; Varenicline
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Acronyms RAUORA
  • Most Recent Events

    • 30 Nov 2017 New trial record
    • 28 Nov 2017 According to an Achieve Life Sciences media release, today announced an agreement with Auckland UniServices Limited, as the commercial arm of the University of Auckland, to provide cytisine for use in the Phase 3 "RAUORA" clinical trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top